EA201190274A1 - Конструкции casb7439 - Google Patents

Конструкции casb7439

Info

Publication number
EA201190274A1
EA201190274A1 EA201190274A EA201190274A EA201190274A1 EA 201190274 A1 EA201190274 A1 EA 201190274A1 EA 201190274 A EA201190274 A EA 201190274A EA 201190274 A EA201190274 A EA 201190274A EA 201190274 A1 EA201190274 A1 EA 201190274A1
Authority
EA
Eurasian Patent Office
Prior art keywords
casb7439
constructions
methods
compounds
increasing
Prior art date
Application number
EA201190274A
Other languages
English (en)
Other versions
EA020617B1 (ru
Inventor
Норманд Блэйс
Мартин Харви
Энтони Пилорге
Клеман Риу
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201190274A1 publication Critical patent/EA201190274A1/ru
Publication of EA020617B1 publication Critical patent/EA020617B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям и способам увеличения рекомбинантной продукции полипептидов CASB7439 и к способам их применения.
EA201190274A 2009-05-27 2010-05-25 Конструкции casb7439 EA020617B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18138009P 2009-05-27 2009-05-27
US22039609P 2009-06-25 2009-06-25
PCT/EP2010/057141 WO2010136443A1 (en) 2009-05-27 2010-05-25 Casb7439 constructs

Publications (2)

Publication Number Publication Date
EA201190274A1 true EA201190274A1 (ru) 2012-06-29
EA020617B1 EA020617B1 (ru) 2014-12-30

Family

ID=42556967

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190274A EA020617B1 (ru) 2009-05-27 2010-05-25 Конструкции casb7439

Country Status (19)

Country Link
US (1) US8916514B2 (ru)
EP (1) EP2435469A1 (ru)
JP (1) JP2012528106A (ru)
KR (1) KR20120014054A (ru)
CN (1) CN102459324B (ru)
AU (1) AU2010252012A1 (ru)
BR (1) BRPI1012078A2 (ru)
CA (1) CA2763486A1 (ru)
CL (1) CL2011002994A1 (ru)
CO (1) CO6400229A2 (ru)
DO (1) DOP2011000348A (ru)
EA (1) EA020617B1 (ru)
IL (1) IL216351A0 (ru)
MA (1) MA33409B1 (ru)
MX (1) MX2011012623A (ru)
NZ (1) NZ596501A (ru)
PE (1) PE20120400A1 (ru)
SG (1) SG176220A1 (ru)
WO (1) WO2010136443A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
SI2266603T1 (sl) * 2000-10-18 2012-12-31 Glaxosmithkline Biologicals S.A. Tumorska cepiva
US20140171626A1 (en) * 2012-12-19 2014-06-19 Glaxosmithkline Llc Protein purification
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
HUE067838T2 (hu) * 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300883A (es) 1992-02-18 1994-08-31 Smithkline Beecham Corp Polipeptidos de vacuna.
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
KR100365986B1 (ko) 1996-02-09 2003-02-20 스미스클라인 비이참 바이오로지칼즈 에스.에이. 수두대상포진바이러스유전자63생성물에대한백신
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
NZ506602A (en) 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
AU5788900A (en) 1999-07-07 2001-01-22 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
IL151097A0 (en) * 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
UA79735C2 (ru) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищение антигенов вируса гепатита b (hbv) для использования в вакцинах
US8039602B2 (en) 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
GB0104259D0 (en) * 2001-02-21 2001-04-11 Smithkline Beecham Biolog Novel compounds
GB0111974D0 (en) * 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
MXPA05002287A (es) 2002-08-29 2005-08-18 Genentech Inc 2 polipeptidos similares a achaete-scute y acidos nucleicos de codificacion, y metodos para el diagnostico y tratamiento de tumores.
EP2066810A2 (en) * 2006-09-08 2009-06-10 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of colon cancer
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy

Also Published As

Publication number Publication date
DOP2011000348A (es) 2012-01-15
CN102459324B (zh) 2014-07-09
CA2763486A1 (en) 2010-12-02
NZ596501A (en) 2013-11-29
MA33409B1 (fr) 2012-07-03
CN102459324A (zh) 2012-05-16
US8916514B2 (en) 2014-12-23
EA020617B1 (ru) 2014-12-30
EP2435469A1 (en) 2012-04-04
SG176220A1 (en) 2011-12-29
KR20120014054A (ko) 2012-02-15
PE20120400A1 (es) 2012-05-04
WO2010136443A1 (en) 2010-12-02
US20120070491A1 (en) 2012-03-22
CL2011002994A1 (es) 2012-07-20
BRPI1012078A2 (pt) 2019-09-24
JP2012528106A (ja) 2012-11-12
AU2010252012A1 (en) 2011-12-22
CO6400229A2 (es) 2012-03-15
IL216351A0 (en) 2012-01-31
MX2011012623A (es) 2011-12-14

Similar Documents

Publication Publication Date Title
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
EA201190274A1 (ru) Конструкции casb7439
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EP2350286A4 (en) PREPARATION OF RECOMBINANT NELL PROTEINS
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201270149A1 (ru) Ингибиторы bace
EP2242505A4 (en) GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
IN2014CN03072A (ru)
MY186066A (en) Anti-phf-tau antibodies and their uses
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
DK3354657T3 (da) Fremgangsmåde til fremstilling af planteafledte proteiner
BR112013028251A2 (pt) polipeptídeo
PL3299380T3 (pl) Sposoby oczyszczania polipeptydów
EP2499255A4 (en) EFFICIENT PRODUCTION OF PEPTIDES
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
CR20150271A (es) Peptidos como agonistas de oxitocina
EA201291065A1 (ru) Антитела против vla-4
BR112013028039A2 (pt) composição de cimento
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
EA201690793A1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU